Aligos Therapeutics, Inc. (ALGS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Aligos Therapeutics, Inc. (ALGS) trades at $5.74 with AI Score 17/100 (Grade F). Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for viral and liver diseases. Market cap: $35.52M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026ALGS stock analysis for 2026: Analysts have set a consensus price target of $20.00 for Aligos Therapeutics, Inc., suggesting 248.4% upside from the current price of $5.74. The AI MoonshotScore is 17/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
ALGS: 3/7 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Aligos Therapeutics, Inc. (ALGS) Healthcare & Pipeline Overview
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to addressing unmet medical needs in viral and liver diseases like chronic hepatitis B and NASH. Their pipeline features multiple clinical trials and strategic collaborations, positioning them within the competitive biotechnology sector.
What Is the Investment Thesis for ALGS?
Aligos Therapeutics operates in the high-growth biotechnology sector, focusing on treatments for viral and liver diseases. The company's pipeline, featuring ALG-010133 and ALG-000184 for CHB, represents a significant value driver. Positive outcomes from ongoing Phase Ib and Phase I clinical trials could serve as major catalysts. Strategic collaborations with Luxna Biotech, Emory University, Katholieke Universiteit Leuven, and Merck provide additional validation and potential revenue streams. However, the company's negative profit margin of -1919.7% and negative free cash flow of $-0.07B highlight financial risks. The high beta of 2.75 indicates significant volatility. Successful clinical trials and partnership milestones are essential for driving shareholder value.
Based on FMP financials and quantitative analysis
ALGS Key Highlights
- Market Cap of $35.52M reflects the company's current valuation in the biotechnology sector.
- P/E ratio of -1.38 indicates the company is currently unprofitable.
- Profit Margin of -1919.7% shows significant losses relative to revenue.
- Gross Margin of 89.0% suggests strong potential profitability if operating expenses are managed effectively.
- Free Cash Flow of $-0.07B indicates the company is burning cash and may need additional financing.
Who Are ALGS's Competitors?
ALGS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ALGS's Key Strengths?
- Innovative pipeline of drug candidates targeting unmet medical needs.
- Strategic collaborations with leading research institutions and pharmaceutical companies.
- Experienced management team with expertise in drug development.
- Proprietary technology platforms for developing novel therapeutics.
What Are ALGS's Weaknesses?
- High operating losses and negative free cash flow.
- Dependence on successful clinical trial outcomes.
- Limited commercialization experience.
- Small company size with limited resources.
What Could Drive ALGS Stock Higher?
- Phase Ib clinical trial results for ALG-010133 in chronic hepatitis B.
- Phase I clinical trial results for ALG-000184 in chronic hepatitis B.
- Phase 1a/1b clinical trial progress for ALG-055009 in non-alcoholic steatohepatitis (NASH).
- Advancement of siRNA drug candidate ALG-125755 through preclinical and clinical development.
- Progress in collaborations with Luxna Biotech, Emory University, Katholieke Universiteit Leuven, and Merck.
What Are the Key Risks for ALGS?
- Financial-distress signal — its Altman Z-Score of -17.63 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or unexpected safety issues with drug candidates.
- Regulatory delays or rejection of drug approval applications.
- Competition from established pharmaceutical companies and other biotech firms.
- High operating losses and need for additional financing.
- Patent disputes and intellectual property infringement.
What Are the Growth Opportunities for ALGS?
- Advancement of ALG-010133 in CHB Treatment: ALG-010133, currently in Phase Ib clinical trials, targets chronic hepatitis B, a market with a significant unmet need. Successful trial outcomes and subsequent regulatory approval could lead to substantial revenue. The global hepatitis B therapeutics market is projected to reach billions of dollars, offering a large addressable market for Aligos.
- Development of ALG-000184 for CHB: ALG-000184, a capsid assembly modulator in Phase I clinical trials, represents another growth opportunity in the CHB space. Positive clinical data could position it as a novel treatment option. The CHB market is driven by the chronic nature of the disease and the need for more effective therapies.
- Progression of ALG-055009 for NASH: ALG-055009, a small molecule THR-ß agonist in Phase 1a/1b trials, targets non-alcoholic steatohepatitis (NASH). The NASH market is expected to grow rapidly due to the increasing prevalence of obesity and diabetes. Successful development could provide Aligos with a significant share of this expanding market.
- Expansion of siRNA Drug Candidate ALG-125755: The siRNA drug candidate ALG-125755, along with ALG-125097 and ALG-125819, which have demonstrated potent inhibition of HBsAg release from HBV-infected cells, presents a growth opportunity in HBV treatment. Further development and clinical trials could lead to a novel therapeutic approach.
- Strategic Collaborations and Licensing Agreements: Aligos' collaborations with Luxna Biotech, Emory University, Katholieke Universiteit Leuven, and Merck provide access to new technologies and markets. These partnerships can accelerate drug development and commercialization, enhancing the company's growth prospects. Licensing agreements also provide potential revenue streams through royalties and milestone payments.
What Opportunities Does ALGS Have?
- Growing market for viral and liver disease therapeutics.
- Potential for breakthrough therapies with significant clinical benefits.
- Expansion of pipeline through internal research and external collaborations.
- Strategic partnerships to accelerate drug development and commercialization.
What Threats Does ALGS Face?
- Regulatory hurdles and delays in drug approval.
- Competition from established pharmaceutical companies and other biotech firms.
- Clinical trial failures and unexpected safety issues.
- Patent disputes and intellectual property infringement.
What Are ALGS's Competitive Advantages?
- Proprietary drug candidates targeting specific viral and liver diseases.
- Strategic collaborations with leading research institutions and pharmaceutical companies.
- Intellectual property protection through patents and exclusive licenses.
What Does ALGS Do?
Aligos Therapeutics, Inc. was founded in 2018 and is headquartered in South San Francisco, California. The company focuses on developing novel therapeutics to address unmet medical needs in viral and liver diseases. Their lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer currently in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB). Another key candidate is ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials for CHB. Aligos is also developing ALG-020572, an antisense oligonucleotide designed to prevent HBsAg translation and secretion, and ALG-055009, a small molecule THR-ß agonist in Phase 1a/1b for the treatment of non-alcoholic steatohepatitis (NASH). The company's pipeline also includes siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, which have demonstrated potent inhibition of HBsAg release from HBV-infected cells. Aligos has established collaborations with Luxna Biotech Co., Ltd., Emory University, Katholieke Universiteit Leuven, and Merck to develop and commercialize its products and technologies.
What Products and Services Does ALGS Offer?
- Develop novel therapeutics for viral diseases.
- Focus on unmet medical needs in liver diseases.
- Advance ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer, for chronic hepatitis B (CHB) treatment.
- Develop ALG-000184, a capsid assembly modulator, for CHB treatment.
- Develop ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion.
- Develop ALG-055009, a small molecule THR-ß agonist for non-alcoholic steatohepatitis (NASH) treatment.
- Develop siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, which demonstrated potent inhibition of HBsAg release from HBV-infected cells.
How Does ALGS Make Money?
- Develop and commercialize novel therapeutics for viral and liver diseases.
- Generate revenue through licensing agreements and collaborations with other companies.
- Advance drug candidates through clinical trials to obtain regulatory approval and market access.
What Industry Does ALGS Operate In?
Aligos Therapeutics operates within the competitive biotechnology industry, which is characterized by high R&D spending, regulatory hurdles, and potential for significant returns. The company focuses on viral and liver diseases, aligning with the growing need for innovative treatments in these areas. The hepatitis B and NASH markets are substantial, with increasing prevalence and limited treatment options. Competition includes established pharmaceutical companies and other biotech firms developing similar therapies. Aligos' success depends on its ability to navigate the complex regulatory landscape and demonstrate clinical efficacy.
Who Are ALGS's Key Customers?
- Patients suffering from chronic hepatitis B (CHB).
- Patients suffering from non-alcoholic steatohepatitis (NASH).
- Pharmaceutical companies through licensing and collaboration agreements.
Aligos Therapeutics, Inc. (ALGS) Valuation Context
Valued at $35.52M, ALGS is classified as a micro-cap stock. Relative to its peer group, ALGS's quantitative score of 17/100 is below the peer average of 76/100.
ALGS Revenue & Earnings Trend
In Q1 2026, ALGS generated $2.8M in top-line revenue, marking a sequential increase of 1574.6%. The company recorded a net loss of $23.0M, with diluted EPS of $-2.21. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ALGS averaged $-2.17 in diluted EPS.
Company Profile
Aligos Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Lawrence Blatt. ALGS has traded publicly since 2020.
Key Financial Metrics
A current ratio of 2.56 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -152.3%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Aligos Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -17.63 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Aligos Therapeutics, Inc. revenue of about $19.9M for fiscal 2026, with EPS near $-7.05. The estimate reflects 4 contributing analysts.
ALGS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those in the know see value, potentially signaling undervalued stock.
- The community is buzzing about potential partnerships, indicating future growth opportunities.
- Positive sentiment around ALGS's innovative approach to liver disease treatment is creating market excitement.
- Despite recent volatility, there's a strong belief in the long-term potential of their drug pipeline, like the early days of Moderna’s mRNA tech.
Bear Case
- Mixed community sentiment indicates uncertainty regarding ALGS's clinical trial outcomes.
- Recent market perception suggests concerns about competition in the liver disease therapeutics space.
- Bearish community views highlight the risk of clinical trial failures, reminiscent of Biogen's Alzheimer's drug setbacks.
- Insider activity, while showing some buying, also includes selling, creating mixed signals about internal confidence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3M | -$23M | -$2.21 |
| Q4 2025 | $169,000 | -$20M | -$1.91 |
| Q3 2025 | $741,000 | -$32M | -$3.04 |
| Q2 2025 | $965,000 | -$16M | -$1.53 |
Based on FMP financials and quantitative analysis
ALGS Latest News
-
Why Akamai Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket
benzinga · May 8, 2026
ALGS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALGS.
Price Targets
Consensus target: $20.00
ALGS MoonshotScore
What does this score mean?
The MoonshotScore rates ALGS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Lawrence Blatt
CEO
Lawrence Blatt serves as the CEO of Aligos Therapeutics, bringing extensive experience in the biopharmaceutical industry. His background includes leadership roles in various biotech companies, where he focused on drug discovery and development. He has a proven track record of advancing innovative therapies through clinical trials and securing strategic partnerships. Blatt's expertise spans multiple therapeutic areas, including virology and liver diseases. His educational background includes advanced degrees in relevant scientific disciplines.
Track Record: Under Lawrence Blatt's leadership, Aligos Therapeutics has advanced multiple drug candidates into clinical trials, including ALG-010133 and ALG-000184 for chronic hepatitis B. He has also secured key collaborations with Luxna Biotech, Emory University, Katholieke Universiteit Leuven, and Merck. These achievements reflect his strategic vision and ability to drive innovation within the company.
What Investors Ask About Aligos Therapeutics, Inc. (ALGS) — Healthcare
What does Aligos Therapeutics, Inc. do?
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for viral and liver diseases. Their primary focus is on addressing unmet medical needs in areas such as chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH). The company's pipeline includes multiple drug candidates in various stages of clinical development, including ALG-010133 and ALG-000184 for CHB, and ALG-055009 for NASH. Aligos also engages in strategic collaborations to accelerate drug development and commercialization.
What do analysts say about ALGS stock?
Analyst coverage of Aligos Therapeutics, Inc. (ALGS) is limited, reflecting its small market capitalization and early-stage clinical development. Key valuation metrics include market capitalization and cash burn rate. Growth considerations center on the successful advancement of its drug candidates through clinical trials and potential partnerships. Analyst consensus is contingent on positive clinical data and regulatory milestones. Investors should conduct their own due diligence and consider the inherent risks associated with biotechnology investments.
What are the main risks for ALGS?
Aligos Therapeutics faces several key risks inherent to the biotechnology industry. Clinical trial failures or unexpected safety issues with its drug candidates could significantly impact its valuation. Regulatory delays or rejection of drug approval applications pose another substantial risk. The company also faces competition from established pharmaceutical companies and other biotech firms developing similar therapies. High operating losses and the need for additional financing are ongoing concerns. Patent disputes and intellectual property infringement also represent potential risks.
What are the key factors to evaluate for ALGS?
Aligos Therapeutics, Inc. (ALGS) holds an AI score of 17/100 (low). Analysts target $20.00 (+248%). Not financial advice.
How frequently does ALGS data refresh on this page?
ALGS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ALGS's recent stock price performance?
Aligos Therapeutics, Inc. (ALGS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline of drug candidates targeting unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ALGS overvalued or undervalued right now?
Valuing Aligos Therapeutics, Inc. (ALGS) requires multiple metrics. Analysts target $20.00 (+248%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ALGS?
Before investing in Aligos Therapeutics, Inc. (ALGS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- Clinical trial outcomes are inherently uncertain and may impact future results.